Patents by Inventor Giora Carni
Giora Carni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9801826Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: GrantFiled: January 11, 2017Date of Patent: October 31, 2017Assignee: INTEC PHARMA LTD.Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Patent number: 9693981Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.Type: GrantFiled: October 19, 2009Date of Patent: July 4, 2017Assignee: INTEC PHARMA LTD.Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
-
Patent number: 9655859Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: GrantFiled: February 3, 2016Date of Patent: May 23, 2017Assignee: INTEC PHARMA LTD.Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Publication number: 20170119679Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: ApplicationFiled: January 11, 2017Publication date: May 4, 2017Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Publication number: 20170119664Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: January 11, 2017Publication date: May 4, 2017Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20170087091Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: ApplicationFiled: February 3, 2016Publication date: March 30, 2017Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Patent number: 9554991Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: GrantFiled: January 14, 2016Date of Patent: January 31, 2017Assignee: INTEC PHARMA LTD.Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20160220495Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about I 0 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: ApplicationFiled: February 3, 2016Publication date: August 4, 2016Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Publication number: 20160199300Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: January 14, 2016Publication date: July 14, 2016Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Patent number: 9259387Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: GrantFiled: May 18, 2015Date of Patent: February 16, 2016Assignee: INTEC PHARMA LTD.Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20150366832Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: May 18, 2015Publication date: December 24, 2015Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Patent number: 9072663Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: GrantFiled: July 2, 2014Date of Patent: July 7, 2015Assignee: INTEC PHARMA LTD.Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20150010624Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20140314842Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Patent number: 8771730Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: GrantFiled: April 17, 2009Date of Patent: July 8, 2014Assignee: Intec Pharma Ltd.Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20140017303Abstract: The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.Type: ApplicationFiled: November 1, 2011Publication date: January 16, 2014Applicant: INTEC PHARMA LTD.Inventors: Nadav Navon, David Kirmayer, Julia Shvetz, Elena Kluev, Eva Abramov, Zeev Weiss, Giora Carni
-
Publication number: 20120321706Abstract: Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug.Type: ApplicationFiled: October 19, 2010Publication date: December 20, 2012Applicant: INTEC PHARMA LTD.Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
-
Publication number: 20120021051Abstract: A biodegradable, multi-layered controlled release gastroretentive dosage form which is optionally divided into a first dosage of zaleplon for controlled release and a second dosage of zaleplon for immediate release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the gastroretentive dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide efficient sleep induction with good sleep maintenance and minimal next day residual effects.Type: ApplicationFiled: October 19, 2009Publication date: January 26, 2012Applicant: Intec Pharma Ltd.Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
-
Publication number: 20110117192Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: April 17, 2009Publication date: May 19, 2011Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20110091542Abstract: A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates upon contact with gastric juice and the dosage form unfolds rapidly upon contact with gastric juice. The biodegradable, multi-layered gastroretentive dosage forms of the invention provide fast onset of baclofen or R-baclofen activity with prolonged absorption and minimal undesirable side effects.Type: ApplicationFiled: June 9, 2010Publication date: April 21, 2011Inventors: Nadav Navon, Julia Shvetz, Eytan Moor, David Kirmayer, Elena Kluev, Shuher Masri, Giora Carni, Zeev Weiss